Appendix Table F-2. Study characteristics—KQ 2

| **Study:****Author****Year****Acronym** | **Study Design; Setting;** **Location;****Funding Source;****Quality** | **Tools Assessed** | **Total N** | **Mean Follow up period** | **Mean Age (years)** | **Special Population** |
| --- | --- | --- | --- | --- | --- | --- |
| Apostolakis, 2012[39](#_ENREF_39)AMADEUS | RCT;NR;US, Canada, UK, Europe, Australia/NZ;Industry;Low risk of bias | HEMORR2HAGESHAS-BLEDATRIA | 2,293 | Total: 429 days (+/- 118) | Total: 70.2 (SD 9.1) | None |
| Friberg, 2012[1](#_ENREF_1)Swedish Atrial Fibrillation cohort study | Prospective cohort;Inpatient, Outpatient;Europe;Government, Nongovernment, Nonindustry;Low risk of bias | CHADS2 scoreCHA2DS2-VASc scoreFramingham scoreHAS-BLEDHEMORR2HAGES | 170,291 | Total: Median 1.4 yr (IQR 1.8) | Total: 76.2 | None |
| Gallego, 2012[40](#_ENREF_40) | Retrospective cohort;Outpatient;Europe, NR;Government;Unclear | HAS-BLED | 965 | Total: Median 861 days | Total: Median 76 (IQR 70-81) | Patients in the therapeutic range |
| Lip, 2012[41](#_ENREF_41)Loire Valley Atrial Fibrillation Project | Retrospective cohort;Inpatient;Europe;NR;Unclear | HAS-BLEDHEMORR2HAGESATRIABleeding Risk Index | 7,156 | NR | Arm 1: 77.7 (SD 8.2)Arm 2:73.8 (SD 11.6)Arm 3:49.0 (SD 13.1) | None |
| Naganuma, 2012[3](#_ENREF_3) | Retrospective cohort;Outpatient;AsiaNongovernment, Nonindustry;Low risk of bias | CHADS2 score - LowHAS-BLED - Unclear | 845 | Total: Median 27 mo | Total: Median 74 | None |
| Roldan, 2012[42](#_ENREF_42) | Retrospective cohort;Outpatient;Europe;NR;Unclear | ATRIAHAS-BLED | 937 | Total: Median 952 days (IQR 785-1074) | Total: Median 76 (IQR 70-81) | Patients in the therapeutic range |
| Ruiz-Nodar, 2012[8](#_ENREF_8) | Retrospective cohort;NR;Europe;NR;High risk of bias | HAS-BLEDCHA2DS2-VASc score | 590 | Total: ~12 mo | Total: 72.2 (SD 8.1) | None |
| Fang, 2011[43](#_ENREF_43)ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) | Retrospective cohort;Outpatient;US;Government, Industry, Nongovernment, Nonindustry;Low risk of bias | ATRIAHEMORR2HAGESBleeding Risk Index | 9,186 | Total: Median 3.5 yr (IQR 1.2-6.0) | NR | None |
| Lind, 2011[2](#_ENREF_2) | Retrospective cohort;Outpatient;Europe;NR;High risk of bias | INR | 19,180 | NR | NR | None |
| Lip, 2011[44](#_ENREF_44)SPORTIF (Stroke Prevention using an ORal Thrombin Inhibitor in atrialFibrillation) | RCT;Outpatient;NR;Industry;Low risk of bias | HAS-BLEDCHADS2 score | 7,329 | NR | Arm 1: 73.9 (SD 8.6)Arm 2: 70.9 (SD 8.9) | None |
| Olesen, 2011[11](#_ENREF_11) | Retrospective cohort;Inpatient;Europe;NR;High risk of bias | CHADS2 scoreCHA2DS2-VASc score | 132,372 | Total: Max 12 | Arm 1: 72.8 (SD 14.4)Arm 2: 70.6 (SD 11.1)Arm 3: 78.1 (SD 11.2)Arm 4: 73.1 (SD 9.6) | None |
| Olesen, 2011[45](#_ENREF_45) | Retrospective cohort;Inpatient;Europe;NR;Low risk of bias | HAS-BLEDHEMORR2HAGES | 118,584 | Total: 10  | Arm 1: 78.6 (SD 10.6)Arm 2: 74.7 (SD 13.6)Arm 3: 74.6 (SD 9.2)Arm 4: 71.2 (SD 10.7)\_ | None |
| Poli, 2011[13](#_ENREF_13) | Prospective cohort;NR;Europe;None;Low risk of bias | CHADS2 scoreBleeding Risk Index | 3,302 | Total: Median 2.3 (IQR 0.8 to 4.4) | Total: Median 74 (IQR 68 to 80) | None |
| Pisters, 2010[46](#_ENREF_46)Euro Heart Survey for AF | Prospective cohort;Inpatient, Outpatient;Europe;Industry;Low risk of bias | HAS-BLEDHEMORR2HAGES | 3,456 | Total: ~1 yr | 66.8 (SD12.8) | None |
| Gage, 2006[47](#_ENREF_47)NRAF (National Registry of Atrial Fibrillation) | Retrospective cohort;Outpatient;US;Government, Nongovernment, Nonindustry;Low risk of bias | HEMORR2HAGESBleeding Risk Index | 3,791 | Total: 0.82 yr (3138 pt-yrs/3791 yrs) | Total: 80.2 | None |
| Shireman, 2006[48](#_ENREF_48) | Retrospective cohort;Outpatient;US;Government;Low risk of bias | Bleeding Risk Index | 26,345 | NR | NR | None |
| Aspinall, 2005[49](#_ENREF_49) | Retrospective cohort;Outpatient;US;None;Low risk of bias | Bleeding Risk Index | 1,269 | NR | Total: 67.9 (SD 11.4) | None |
| Hylek, 2003[34](#_ENREF_34)ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) | Retrospective cohort;Outpatient;US;Government;Low risk of bias | INR | 596 | NR | Arm 1: 79Arm 2: 80Arm 3: 76 | Patients with prior stroke |

**Abbreviations:** AF = atrial fibrillation; IQR = interquartile range; N = number of patients; NR = not reported; RCT = randomized controlled trial; SD = standard deviation